Coupling Genotyping and Computational Modeling in Prediction of Anti-epileptic Drugs that cause Stevens Johnson Syndrome and Toxic Epidermal Necrolysis for Carrier of HLA-B*15:02

J Pharm Pharm Sci. 2016;19(1):147-60. doi: 10.18433/J38G7X.

Abstract

Purpose: The importance of HLA-B*15:02 genotyping to avoid carbamazepine induced SJS/TEN and molecular modeling to predict the role of HLA-B*15:0 and AEDs induced SJS/TEN are investigated.

Methods: DNA was extracted from eighty-six patients. The patients were genotyped by AS-PCR. Computational modeling of the HLA-B*15:02 followed by docking studies were performed to screen 26 AEDs that may induce ADR among HLA-B*15:02 carriers.

Results: Odd ratio for CBZ induced SJS/TEN and HLA-B*15:02 was 609.0 (95% CI: 23-15873; p=0.0002). Molecular modeling studies showed that acetazolamide, ethosuxiamide, lamotrigine, oxcarbazepine, phenobarbital, phenytoin, primidone and sodium-valproate may induce ADR in HLA-B*15:02 carriers alike CBZ. Conclusion. We confirmed HLA-B*15:02 as a predictor of SJS/TEN and recommend pre-screening. Computational prediction of DIHR is useful in personalized medicine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Anticonvulsants / adverse effects*
  • Anticonvulsants / chemistry
  • Carbamazepine / adverse effects*
  • Carbamazepine / chemistry
  • Female
  • Genotype
  • HLA-B Antigens / genetics*
  • Heterozygote*
  • Humans
  • Male
  • Middle Aged
  • Molecular Docking Simulation*
  • Stevens-Johnson Syndrome / drug therapy*
  • Stevens-Johnson Syndrome / genetics*
  • Young Adult

Substances

  • Anticonvulsants
  • HLA-B Antigens
  • Carbamazepine